71370 Federal Register / Vol. 88, No. 198 / Monday, October 16, 2023 / Notices 

3 ICD–11 Overview: Key Facts, History, and 

References (September 2023): https://

ncvhs.hhs.gov/NCVHS-WG-ICD-11-OverviewSeptember-2023. 

4 ICD–11 was adopted at the World Health 

Assembly in May 2019 and Member States 

committed to start using it for mortality and 

morbidity reporting in 2022. Since 2019, early 

adopter countries, translators, and scientific groups 

have recommended further refinements to produce 

the version that is posted online today. World 

Health Organization (WHO) Press Release. 

(February 11, 2022): https://paho.org/en/news/11-2- 

2022-whos-new-international-classificationdiseases-icd-11-comes-effect. 

5WHO ICD–11 website: https://icd.who.int/en. 

6WHO ICD–11 Fact Sheet: https://icd.who.int/en/ 

docs/icd11factsheet_en.pdf. 

updates: https://ncvhs.hhs.gov/ 

meetings/full-committee-meeting-15. 

Background on ICD–11: The 

International Classification of Diseases 

(ICD) is the global standard for health 

data, clinical documentation, and 

statistical aggregation. It provides a 

common language for recording, 

reporting, and monitoring diseases, 

allowing the world to compare and 

share data in a consistent and standard 

way—among hospitals, regions, and 

countries, and over periods of time. It 

facilitates the collection and storage of 

data for analysis and evidence-based 

decision-making by enabling systematic 

recording, reporting, analysis, 

interpretation, and comparison of 

mortality and morbidity data. 

ICD–11 allows countries to count and 

identify their most pressing health 

issues using an up-to-date and clinically 

relevant classification system.3456

Governments assign ICD–11 codes to 

health conditions and accidents so data 

can be used to design effective public 

health policies and measure their 

impacts, or so that clinicians can use the 

data for recording encounters with 

patients in a standard way. 

Request for Information: This Notice 

also serves as a Request for Information 

(RFI) addressing the potential use of 

ICD–11 for morbidity coding in the U.S. 

We welcome responses from industry 

stakeholders, interested individuals and 

organizations, or any members of the 

public. The following questions are a 

guide to information the Workgroup 

would find particularly helpful, though 

respondents are invited to comment on 

any aspect of ICD–11 that they wish. 

1. Related to ICD–11 content and addressing 

U.S.-specific needs, which 

enhancements in classification content 

would be most useful? 

a. Coding to assess and address population 

health equity, social, behavioral, and 

community health 

b. Coding to measure health care quality 

and patient safety 

c. Coding for rare diseases 

d. Content on other topics? 

2. What is the potential to reduce burdens 

and improve quality/accuracy through 

the greater automation offered by the 

ICD–11 online classification systems? 

a. How might automation reduce burdens 

of clinical documentation and coding for 

reimbursement, risk adjustment, clinical 

registry, and public health reporting? 

b. What might be the role of artificial 

intelligence for your organization? 

c. What might be the role of standardized 

cross-maps to other coding systems? 

d. What other potential features could 

promote burden reduction? 

3. What standards, systems, workforce, and 

processes must change to accommodate 

ICD–11? 

a. How would your organization assess the 

cost and impact of these changes? 

b. How might technical changes such as 

clustered (post-coordinated) coding be 

implemented in your environment? 

c. What other changes are related? 

4. What are the most important 

considerations and requirements for a 

U.S. governing body for ICD–11? 

a. Developing and managing 

implementation plans and programs for 

ICD–11 in the U.S. 

b. Developing regulations or guidance for 

ICD–11 applicable to your organization. 

c. Ongoing management and maintenance 

of U.S. ICD–11 and its use. 

d. Other requirements not named above? 

5. What financial, educational, or human 

resources will be needed for: 

a. Implementing ICD–11 in your 

organization. 

b. Managing and maintaining U.S. ICD–11 

in your organization. 

c. Meeting the needs of smaller, less 

resourced, or less externally supported 

entities. 

d. What other resources not listed here may 

be needed? 

The Committee will compile 

submitted responses and consider them 

together with responses submitted in 

response to the initial ICD–11 RFI 

[https://ncvhs.hhs.gov/wp-content/ 

uploads/2023/07/RFI-ResponsesNCVHS-Workgroup-on-Timely-andStrategic-Action-to-Inform-ICD-11- 

Policy.pdf] together with input from 

subject matter experts during the August 

3, 2023, ICD–11 Expert Roundtable 

meeting [https://ncvhs.hhs.gov/ 

meetings/icd-11-workgroup-meeting/]. 

To submit comments in response to the 

RFI, please send by January 12, 2024, to 

NCVHSmail@cdc.gov and include on 

the subject line: Response from [your 

organization or name] regarding ICD–11 

RFI. 

Sharon Arnold, 

Associate Deputy Assistant Secretary, Office 

of Science and Data Policy, Office of the 

Assistant Secretary for Planning and 

Evaluation. 

[FR Doc. 2023–22753 Filed 10–13–23; 8:45 am] 

BILLING CODE 4150–05–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Neurodegenerative Disorders and 

Aging. 

Date: November 7, 2023. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jessica Bellinger, Ph.D., 

Scientific Review Administrator, Center for 

Scientific of Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3158, 

Bethesda, MD 20892, 301–827–4446, 

bellingerjd@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Genes, Genomes and Genetics. 

Date: November 8–9, 2023. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Bethesdan Hotel, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Linda Wagner Jurata, 

Ph.D., Scientific Review Officer, The Center 

for Scientific Review, The National Institutes 

of Health, 6701 Rockledge Drive, Bethesda, 

MD 20892, (301) 496–8032, linda.jurata@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Biomedical Sensing, Measurement 

and Instrumentation. 

Date: November 8–9, 2023. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Steven Anthony Ripp, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–3010, steven.ripp@nih.gov. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 198 / Monday, October 16, 2023 / Notices 71371 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Alzheimer’s Disease and its Related 

Dementias. 

Date: November 8–9, 2023. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Mariam Zaka, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1009J, 

Bethesda, MD 20892, (301) 435–1042, 

zakam2@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Motor System, Pain, and Olfaction. 

Date: November 8, 2023. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kirk Thompson, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5184, 

MSC 7844, Bethesda, MD 20892, 301–435– 

1242, kgt@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Myalgic 

Encephalomyelitis-Chronic Fatigue 

Syndrome. 

Date: November 8, 2023. 

Time: 11:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Roger Janz, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 402–8515, janzr2@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 11, 2023. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2023–22770 Filed 10–13–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; AREA/ 

REAP: Musculoskeletal, Oral, and Skin 

Sciences. 

Date: November 7, 2023. 

Time: 9:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Richard Ingraham, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4116, 

MSC 7814, Bethesda, MD 20892, (301) 496– 

8551, ingrahamrh@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Musculoskeletal, Rehabilitation 

and Skin Sciences. 

Date: November 7–8, 2023. 

Time: 1:30 p.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Richard Ingraham, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4116, 

MSC 7814, Bethesda, MD 20892, (301) 496– 

8551, ingrahamrh@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Chemistry, Biochemistry and 

Biophysics. 

Date: November 8–9, 2023. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Dennis Pantazatos, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–2381, dennis.pantazatos@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Neurodevelopment and Plasticity. 

Date: November 9, 2023. 

Time: 12:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Vanessa S. Boyce, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm. 4185, 

MSC 7850, Bethesda, MD 20892, (301) 402– 

3726, boycevs@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Research 

Enhancement Awards: Molecular Genetics, 

Cellular & Cancer Biology. 

Date: November 13, 2023. 

Time: 1:00 p.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Brian Paul Chadwick, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–3586, chadwickbp@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Psychopathology. 

Date: November 13, 2023. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Stephanie Christine Nagle 

Emmens, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 594–6604, 

nagleemmenssc@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Cell Biology, Developmental 

Biology, and Bioengineering. 

Date: November 14, 2023. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Alexander Gubin, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4196, 

MSC 7812, Bethesda, MD 20892, 301–435– 

2902, gubina@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Drug Discovery for Aging, 

Neurodegenerative and Neurological 

Disorders. 

Date: November 16–17, 2023. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Kathryn Partlow, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1016D, 


ddrumheller on DSK120RN23PROD with NOTICES1